(Q27023893)

non-alcoholic fatty liver

inferred from title

1 reference

1 reference

Xiao J

1

1 reference

Guo R

2

1 reference

Fung ML

3

1 reference

Liong EC

4

1 reference

Tipoe GL

5

1 reference

language of work or name

1 reference

April 2013

1 reference

Hepatobiliary & Pancreatic Diseases International

published in

1 reference

volume

12

1 reference

issue

2

1 reference

page(s)

125-35

1 reference

Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Prevalence of fatty liver in children and adolescents.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Epidemiology of non-alcoholic fatty liver disease in China.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

NAFLD in the absence of metabolic syndrome: different epidemiology, pathogenetic mechanisms, risk factors for disease progression?

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Dyslipidemia in patients with nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link?

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Mechanisms of disease progression in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Molecular mechanisms involved in NAFLD progression

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

The next generation of obesity research: no time to waste

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Bariatric surgery worldwide 2003.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Obesity and weight management in the elderly.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Obesity, weight loss and prognosis in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

A comparison of body mass index, waist-hip ratio and waist circumference as predictors of all-cause mortality among the elderly: the Rotterdam study

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Body weight and weight change and their health implications for the elderly.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Sucrose compared with artificial sweeteners: different effects on ad libitum food intake and body weight after 10 wk of supplementation in overweight subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Dietary composition during weight-loss maintenance

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Effect of weight reduction on hepatic abnormalities in overweight patients

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Healthy-lifestyle behaviors associated with overweight and obesity in US rural children

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Benefits of lifestyle modification in NAFLD.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Exercise training increases lipid metabolism gene expression in human skeletal muscle

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Regular exercise is associated with a reduction in the risk of NAFLD and decreased liver enzymes in individuals with NAFLD independent of obesity in Korean adults

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Independent effects of physical activity in patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Exercise and the liver: implications for therapy in fatty liver disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Exercise protects against high-fat diet-induced hypothalamic inflammation.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Exercise training attenuates hepatic inflammation, fibrosis and macrophage infiltration during diet induced-obesity in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Physiologic action of glucagon on liver glucose metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

RETRACTED: Hepatic glucagon action is essential for exercise-induced reversal of mouse fatty liver

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Herbal medicines--what's in the bottle?

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Resveratrol: French paradox revisited

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Resveratrol inhibits nonalcoholic fatty liver disease in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Green tea extract protects leptin-deficient, spontaneously obese mice from hepatic steatosis and injury

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Epigallocatechin-3-gallate improves nonalcoholic steatohepatitis model mice expressing nuclear sterol regulatory element binding protein-1c in adipose tissue.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Green tea extract attenuates hepatic steatosis by decreasing adipose lipogenesis and enhancing hepatic antioxidant defenses in ob/ob mice

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Mechanisms for insulin resistance: common threads and missing links

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Journeys of the Circle: a culturally congruent life skills intervention for adolescent Indian drinking

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

The role of metformin in the management of NAFLD

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Pioglitazone: side effect and safety profile

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Overview of metformin: special focus on metformin extended release

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Metformin in the treatment of patients with non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Histopathology of pediatric nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Acute sympathoinhibitory actions of metformin in spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

HMG-CoA reductase inhibitors for treatment of hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Statins and hepatotoxicity: focus on patients with fatty liver

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

A pilot trial of pentoxifylline in nonalcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis--a randomized and controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Gut--liver axis: the impact of gut microbiota on non alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Metabolic syndrome and risk factors for non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Review article: fructose in non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

What should we recommend to our patients with NAFLD regarding alcohol use?

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Second-hand smoke stimulates lipid accumulation in the liver by modulating AMPK and SREBP-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

Weight reduction for non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960021-1

7 January 2021

10.1016/S1499-3872(13)60021-1

Identifiers

DOI

0 references

Fatcat ID

release_zcrs33olhjb3hhm5edbd2ed37i

0 references

PubMed publication ID

23558065

1 reference